Treatment of Campylobacter Gastritis with Bismuth Salts

  • C. A. M. McNulty
Conference paper


Bismuth compounds have been used for over two centuries for the treatment of various gastrointestinal disorders because of their local protective demulcent, antacid and antidiarrhoeal properties. Bismuth salts also have an antimicrobial effect against Campylobacter pylori (McNulty et al. 1985) and other gastrointestinal pathogens (Manhart 1984).


Gastric Mucosa Duodenal Ulcer Endoscopic Appearance Public Health Laboratory Bismuth Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fullman H, Van Deventer G, Schaneidman D et al. (1985) “Healed” duodenal ulcers are histologically ill. Gastroenterology 88:1390Google Scholar
  2. 2.
    Glupczynski Y, Labbe M, Burette A, Delmee M, Avesani V, Bruck C (1987) Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet I:1096CrossRefGoogle Scholar
  3. 3.
    Goodwin CS, Blake P, Blincow E (1986) The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 17:309–314PubMedCrossRefGoogle Scholar
  4. 4.
    Holroyde MJ, Yeakle C, Pebble J (1984) Gastric cytoprotection by bismuth subsalicylate. Gastroenterology 86:1116Google Scholar
  5. 5.
    Jones DM, Eldridge J, Whorwell PJ, Miller JP (1985) The effects of various anti-ulcer regimens and antibiotics on the presence of Campylobacter pyloridis and its antibody. Cam pylobacter III: Proceedings of the Third International Workshop on Campylobacter Infections. Public Health Laboratory Service, London, 161–162Google Scholar
  6. 6.
    Lambert JR, Dunn KL, Turner H et al. (1986) Effect on histological gastritis following eradication of Campylobacter pyloridis. Gastroenterology 90:1509 (abstract)Google Scholar
  7. 7.
    Langenberg ML, Rauws EAJ, Schipper MEI et al. (1985) The pathogenic role of Campylobacter pyloridis, studied by attempts to eliminate these organisms. In: Pearson AD, Skirrow MB, Lior H, Rowe B (eds) Campylobacter III: Proceedings of the Third International Workshop on Campylobacter Infections, Ottawa, 1985. Public Health Laboratory Service, London, 162–163Google Scholar
  8. 8.
    Lanza FL, Rack MF, Peterson DF (1986) Eradication of Campylobacter pyloridis with Bismuth subsalicylate. Am J Gastroenterol 81:853Google Scholar
  9. 9.
    Ligumsky M, Karmeli F, Rachmilewitz D (1984) Sucralfate stimulation of gastric PGE2 syntheses - possible mechanism to explain its effective cytoprotective properties. Gastroenterology 86:1164Google Scholar
  10. 10.
    Marshall BJ, Armstrong JA, McGeckie DB et al. (1985) The antimicrobial action of bismuth: early results of antibacterial regimens in the treatment of duodenal ulcer. Campylobacter III: Proceedings of the Third International Workshop on Campylobacter Infections. Public Health Laboratory Service, London, 161Google Scholar
  11. 11.
    McNulty CAM, Watson DM (1984) Spiral bacteria of the gastric antrum. Lancet 1:1068–1069PubMedCrossRefGoogle Scholar
  12. 12.
    McNulty CAM, Dent J, Wise R (1985) Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother 28:837–838PubMedGoogle Scholar
  13. 13.
    McNulty CAM, Gearty JC, Crump B et al. (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Brit Med J 293:645–649CrossRefGoogle Scholar
  14. 14.
    Miller JP, Faragher EB (1986) Relapse of duodenal ulcer: does it matter which drug is used in initial treatment. Brit Med J 293:1117–1118CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • C. A. M. McNulty

There are no affiliations available

Personalised recommendations